Searchable abstracts of presentations at key conferences in endocrinology

ea0099ep219 | Diabetes, Obesity, Metabolism and Nutrition | ECE2024

Non-alcoholic fatty liver disease. change from F3 to F1 fibrosis after 12 months of combined pioglitazone and dulaglutide treatment

Lener Luisa , Chianelli Marco , Graziano Filomena , Misischi Irene , Petrucci Lucilla , Rinaldi Roberta , Papini Enrico , Guglielmi Rinaldo

Background: Liver fibrosis is the result of the chronic hepatocyte damage due to different causes. Among them, Non-alcoholic Fatty Liver Disease (NAFLD) is estimated to account for nearly 30% of cases, representing a leading cause of chronic liver disease. NAFLD can evolve into non-alcoholic steatohepatitis, with or without fibrosis, whose diagnosis requires a liver biopsy, a costly and invasive procedure. Non-invasive tests have recently been proposed to screen patients at ri...